MicroRNAs in T Cell-Immunotherapy

MicroRNAs (miRNAs) act as master regulators of gene expression in homeostasis and disease. Despite the rapidly growing body of evidence on the theranostic potential of restoring miRNA levels in pre-clinical models, the translation into clinics remains limited. Here, we review the current knowledge o...

Descripción completa

Detalles Bibliográficos
Autores principales: Dosil, Sara G., Rodríguez-Galán, Ana, Sánchez-Madrid, Francisco, Fernández-Messina, Lola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820302/
https://www.ncbi.nlm.nih.gov/pubmed/36613706
http://dx.doi.org/10.3390/ijms24010250
_version_ 1784865434207518720
author Dosil, Sara G.
Rodríguez-Galán, Ana
Sánchez-Madrid, Francisco
Fernández-Messina, Lola
author_facet Dosil, Sara G.
Rodríguez-Galán, Ana
Sánchez-Madrid, Francisco
Fernández-Messina, Lola
author_sort Dosil, Sara G.
collection PubMed
description MicroRNAs (miRNAs) act as master regulators of gene expression in homeostasis and disease. Despite the rapidly growing body of evidence on the theranostic potential of restoring miRNA levels in pre-clinical models, the translation into clinics remains limited. Here, we review the current knowledge of miRNAs as T-cell targeting immunotherapeutic tools, and we offer an overview of the recent advances in miRNA delivery strategies, clinical trials and future perspectives in RNA interference technologies.
format Online
Article
Text
id pubmed-9820302
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98203022023-01-07 MicroRNAs in T Cell-Immunotherapy Dosil, Sara G. Rodríguez-Galán, Ana Sánchez-Madrid, Francisco Fernández-Messina, Lola Int J Mol Sci Review MicroRNAs (miRNAs) act as master regulators of gene expression in homeostasis and disease. Despite the rapidly growing body of evidence on the theranostic potential of restoring miRNA levels in pre-clinical models, the translation into clinics remains limited. Here, we review the current knowledge of miRNAs as T-cell targeting immunotherapeutic tools, and we offer an overview of the recent advances in miRNA delivery strategies, clinical trials and future perspectives in RNA interference technologies. MDPI 2022-12-23 /pmc/articles/PMC9820302/ /pubmed/36613706 http://dx.doi.org/10.3390/ijms24010250 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dosil, Sara G.
Rodríguez-Galán, Ana
Sánchez-Madrid, Francisco
Fernández-Messina, Lola
MicroRNAs in T Cell-Immunotherapy
title MicroRNAs in T Cell-Immunotherapy
title_full MicroRNAs in T Cell-Immunotherapy
title_fullStr MicroRNAs in T Cell-Immunotherapy
title_full_unstemmed MicroRNAs in T Cell-Immunotherapy
title_short MicroRNAs in T Cell-Immunotherapy
title_sort micrornas in t cell-immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820302/
https://www.ncbi.nlm.nih.gov/pubmed/36613706
http://dx.doi.org/10.3390/ijms24010250
work_keys_str_mv AT dosilsarag micrornasintcellimmunotherapy
AT rodriguezgalanana micrornasintcellimmunotherapy
AT sanchezmadridfrancisco micrornasintcellimmunotherapy
AT fernandezmessinalola micrornasintcellimmunotherapy

Ejemplares similares